NCT05002868
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of a PARP inhibitor (e.g. Lynparza (olaparib); Patients with symptomatic uncontrolled brain metastasis
https://ClinicalTrials.gov/show/NCT05002868